# Myelosuppression by sunitinib is flt-3 genotype dependent

## Metadata
**Authors:** N P van Erp, R H J Mathijssen, A A van der Veldt, J B Haanen, A K L Reyners, K Eechoute, E Boven, J A M Wessels, H-J Guchelaar, H Gelderblom
**Journal:** British Journal of Cancer
**Date:** 2010 Aug 3
**DOI:** [10.1038/sj.bjc.6605813](https://doi.org/10.1038/sj.bjc.6605813)
**PMID:** 20683446
**PMCID:** PMC2938256
**URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938256/
**PDF:** [https://pmc.ncbi.nlm.nih.gov/articles/PMC2938256/pdf/6605813a.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC2938256/pdf/6605813a.pdf)

## References

1. Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, Patenaude F, Oudard S, Karakiewicz PI (2008) Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53: 917–930  [DOI](https://doi.org/10.1016/j.eururo.2007.11.037) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/18054825/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Eur%20Urol&title=Toxicities%20associated%20with%20the%20administration%20of%20sorafenib,%20sunitinib,%20and%20temsirolimus%20and%20their%20management%20in%20patients%20with%20metastatic%20renal%20cell%20carcinoma&volume=53&publication_year=2008&pages=917&pmid=18054825&doi=10.1016/j.eururo.2007.11.037&)

2. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368: 1329–1338  [DOI](https://doi.org/10.1016/S0140-6736(06)69446-4) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/17046465/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Lancet&title=Efficacy%20and%20safety%20of%20sunitinib%20in%20patients%20with%20advanced%20gastrointestinal%20stromal%20tumour%20after%20failure%20of%20imatinib:%20a%20randomised%20controlled%20trial&volume=368&publication_year=2006&pages=1329&pmid=17046465&doi=10.1016/S0140-6736(06)69446-4&)

3. Hartmann JT, Haap M, Kopp HG, Lipp HP (2009) Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 10: 470–481  [DOI](https://doi.org/10.2174/138920009788897975) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/19689244/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Curr%20Drug%20Metab&title=Tyrosine%20kinase%20inhibitors%20-%20a%20review%20on%20pharmacology,%20metabolism%20and%20side%20effects&volume=10&publication_year=2009&pages=470&pmid=19689244&doi=10.2174/138920009788897975&)

4. Kumar R, Crouthamel MC, Rominger DH, Gontarek RR, Tummino PJ, Levin RA, King AG (2009) Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 101: 1717–1723  [DOI](https://doi.org/10.1038/sj.bjc.6605366) | [PMC free article](/articles/PMC2768111/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/19844230/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Br%20J%20Cancer&title=Myelosuppression%20and%20kinase%20selectivity%20of%20multikinase%20angiogenesis%20inhibitors&volume=101&publication_year=2009&pages=1717&pmid=19844230&doi=10.1038/sj.bjc.6605366&)

5. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115–124  [DOI](https://doi.org/10.1056/NEJMoa065044) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/17215529/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Sunitinib%20versus%20interferon%20alfa%20in%20metastatic%20renal-cell%20carcinoma&volume=356&publication_year=2007&pages=115&pmid=17215529&doi=10.1056/NEJMoa065044&)

6. van Erp NP, Eechoute K, van d V, Haanen JB, Reyners AK, Mathijssen RH, Boven E, van der ST, Baak-Pablo RF, Wessels JA, Guchelaar HJ, Gelderblom H (2009) Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 27: 4406–4412  [DOI](https://doi.org/10.1200/JCO.2008.21.7679) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/19667267/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&title=Pharmacogenetic%20pathway%20analysis%20for%20determination%20of%20sunitinib-induced%20toxicity&volume=27&publication_year=2009&pages=4406&pmid=19667267&doi=10.1200/JCO.2008.21.7679&)
